Extended NICE drug-eluting stent consultation comes to an end:
This article was originally published in Clinica
Next week sees the end of the extended consultation by the UK's National Institute for Health and Clinical Excellence (NICE) on NHS use of drug-eluting stents (DESs) to treat coronary artery disease. After allowing an extra month - to October 1 - for commenting on economic modelling data added to the consultation documentation on August 30 (two days after the original August 28 deadline - see Clinica No 1272, p 7), NICE's first appraisal committee meeting is now due to be held in November. Subject to any appeals process, the final guidance is scheduled for publication in March 2008.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.